CEQUA demonstrated safety and tolerability in clinical trials1-3,a

Most adverse events were mild2

  • The most common adverse events reported in >5% of patients were instillation site pain (22%) and conjunctival hyperemia (6%)1,b
Instillation site pain (N=524)
  • Most ocular adverse events reported by patients treated with CEQUA were mild (80%) or moderate (17%)2
  • Discontinuation rate due to ocular adverse events was 3.2% for CEQUA vs 1.1% for vehicle2

Read the published journal articles that evaluated the safety and efficacy of CEQUA:

Most patients in a clinical trial found CEQUA to be comfortable3

Patients reporting no or mild discomfort in a comfort assessment

Additional safety information

Incidence of blurred vision was <1%2

No reported taste alterations2

In healthy adults, ocular administration of CEQUA led to negligible systemic exposure to cyclosporine2